



CIBMTR[®]

CENTER FOR INTERNATIONAL BLOOD
& MARROW TRANSPLANT RESEARCH

2019 CIBMTR REPORT OF SURVIVAL STATISTICS FOR BLOOD AND MARROW TRANSPLANTS

Guidelines for Interpreting Data

The following tables describe use and outcome of autologous and allogeneic blood and bone marrow transplants in the >500 centers participating in the CIBMTR. Prior to 2007, we estimate the CIBMTR captured 90% of all unrelated donor transplants performed in the US, 60-90% of related donor allogeneic transplants, and 65-75% of autologous transplants. After 2007, the CIBMTR collects data on all allogeneic transplants performed in the US and 80% of autologous transplants.

Table 1-13 (autologous) and Tables 14-36 (allogeneic) show patient characteristics and probabilities of survival ($\pm 95\%$ confidence intervals) at 100-day, 1-, 3- and 5- years post-transplant. Categorical variables are represented by N (%), continuous variables by median (range). Probabilities are calculated using the Kaplan-Meier estimator. Some groups lack sufficient data for calculation of probabilities beyond 2-3 years. These are indicated by footnotes which give the time of the last censored observation. Outcomes are stratified on disease and disease state pre-transplant. However, it should be remembered that these groups are still heterogeneous with regard to age, prior treatment, chemotherapy-sensitivity and other important prognostic factors. Extrapolating to individual patients or centers may not be appropriate.

The enclosed raw data represent a preliminary review of information registered to CIBMTR. The analysis has not been reviewed or approved by the Advisory or Scientific Committee of CIBMTR.

PLEASE NOTE: The enclosed data are for your own information and may be used in oral, but not written presentations. Unauthorized reproduction is prohibited.
Please contact the CIBMTR for information on obtaining written permission to reproduce the enclosed data.

LIST OF TABLES

| |
|---|
| Table 1. Characteristics of patients ≤ 18 years of age receiving autologous transplants for non-Hodgkin lymphoma between July 1999 and June 2017 |
| Table 2. Characteristics of patients > 18 years of age receiving autologous transplant for non-Hodgkin lymphoma between July 1999 and June 2017 |
| Table 3. Characteristics of patients ≤ 18 years of age receiving autologous transplants for Hodgkin's disease between July 1999 and June 2017 |
| Table 4. Characteristics of patients > 18 years of age receiving autologous transplants for Hodgkin's disease between July 1999 and June 2017 |
| Table 5. Characteristics of patients ≤ 18 years of age receiving autologous transplants for acute myelogenous leukemia between July 1999 and June 2017 |
| Table 6. Characteristics of patients > 18 years of age receiving autologous transplants for acute myelogenous leukemia between July 1999 and June 2017 |
| Table 7. Characteristics of patients ≤ 18 years of age receiving autologous transplants for acute lymphoblastic leukemia between July 1999 and June 2017 |
| Table 8. Characteristics of patients > 18 years of age receiving autologous transplants for acute lymphoblastic leukemia between July 1999 and June 2017 |
| Table 9. Characteristics of patients receiving autologous transplants for multiple myeloma between July 1999 and June 2017 |
| Table 10. Characteristics of patients receiving autologous transplants for neuroblastoma between July 1999 and June 2017 |
| Table 11. Characteristics of patients receiving autologous transplants for testicular cancer between July 1999 and June 2017 |
| Table 12. Characteristics of patients ≤ 18 years of age receiving autologous transplants for central nervous system tumors (except CNS lymphoma and neuroblastoma) between July 1999 and June 2017 |
| Table 13. Characteristics of patients > 18 years of age receiving autologous transplants for central nervous system tumors (except CNS lymphoma and neuroblastoma) between July 1999 and June 2017 |
| Table 14. Characteristics of patients receiving HLA-identical sibling transplant for chronic myelogenous leukemia between July 1999 and June 2017 by disease phase |
| Table 15. Characteristics of patients receiving transplant other than HLA-identical sibling for chronic myelogenous leukemia between July 1999 and June 2017 by disease phase |
| Table 16. Characteristics of patients ≤ 18 years of age receiving HLA-identical sibling transplant for acute myelogenous leukemia between July 1999 and June 2017 by remission rate |
| Table 17. Characteristics of patients > 18 years of age receiving HLA-identical sibling transplant for acute myelogenous leukemia between July 1999 and June 2017 by remission state |
| Table 18. Characteristics of patients ≤ 18 years of age receiving transplant from donors other than HLA-identical sibling for acute myelogenous leukemia between July 1999 and June 2017 by remission state |
| Table 19. Characteristics of patients > 18 years of age receiving transplant from donors other than HLA-identical sibling for acute myelogenous leukemia between July 1999 and June 2017 by remission state |
| Table 20. Characteristics of patients ≤ 18 years of age receiving HLA-identical sibling transplant for acute lymphoblastic leukemia between July 1999 and June 2017 by remission state |
| Table 21. Characteristics of patients > 18 years of age receiving HLA-identical sibling transplant for acute lymphoblastic leukemia between July 1999 and June 2017 by remission state |
| Table 22. Characteristics of patients ≤ 18 years of age receiving transplants from donors other than HLA-identical siblings for acute lymphoblastic leukemia between July 1999 and June 2017 by remission state |
| Table 23. Characteristics of patients > 18 years of age receiving transplants from donors other than HLA-identical siblings for acute lymphoblastic leukemia between July 1999 and June 2017 by remission state |

| |
|--|
| Table 24. Characteristics of patients receiving HLA-identical sibling transplants for myelodysplastic syndrome between July 1999 and June 2017 by disease stage |
| Table 25. Characteristics of patients receiving transplants from donors other than HLA-identical siblings for myelodysplastic syndrome between July 1999 and June 2017 by disease stage |
| Table 26. Characteristics of patients receiving HLA-identical sibling transplants for non-Hodgkin lymphoma between July 1999 and June 2017 |
| Table 27. Characteristics of patients receiving transplants from donors other than HLA-identical siblings for non-Hodgkin lymphoma between July 1999 and June 2017 |
| Table 28. Characteristics of patients receiving allogeneic transplants for Hodgkin's disease between July 1999 and June 2017 by donor type |
| Table 29. Characteristics of patients receiving HLA-identical sibling transplants for multiple myeloma between July 1999 and June 2017 by time from diagnosis to transplant |
| Table 30. Characteristics of patients receiving transplants from donors other than HLA-identical siblings for multiple myeloma between July 1999 and June 2017 by time from diagnosis to transplant |
| Table 31. Characteristics of patients ≤ 18 years of age receiving allogeneic transplants for severe aplastic anemia between July 1999 and June 2017 by donor type |
| Table 32. Characteristics of patients > 18 years of age receiving allogeneic transplants for severe aplastic anemia between July 1999 and June 2017 by donor type |
| Table 33. Characteristics of patients receiving allogeneic transplants for Fanconi anemia between July 1999 and June 2017 by donor type |
| Table 34. Characteristics of patients receiving allogeneic transplants for thalassemia between July 1999 and June 2017 by donor type |
| Table 35. Characteristics of patients receiving allogeneic transplants for SCID between July 1999 and June 2017 by donor type |
| Table 36. Characteristics of patients receiving allogeneic transplants for inherited disorders between July 1999 and June 2017 by donor type |
| Appendix. Abbreviations |